References
- Cause-of-death statistics in 2018 in the Republic of Korea. [Internet]. Daejeon: Statistics Korea; 2019 Sep 24 [cited 2019 Oct 13]. Available from: http://kostat.go.kr/portal/korea/kor_nw/1/6/2/index.board?bmode=read&bSeq=&aSeq=377606&pageNo=1&rowNum=10&navCount=10&currPg=&searchInfo=&sTarget=title&sTxt=
- Korean Association for the Study of the Liver. 2019 Korean Association for the Study of the Liver clinical practice guidelines for liver cirrhosis: varices, hepatic encephalopathy and related complications. Seoul: Jin Publishing Co., 2019.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926. https://doi.org/10.1136/bmj.39489.470347.AD
- de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743-752. https://doi.org/10.1016/j.jhep.2015.05.022
- Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003;38:266-272. https://doi.org/10.1016/S0168-8278(02)00420-8
- Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-2261. https://doi.org/10.1056/NEJMoa044456
- Sarin SK, Mishra SR, Sharma P, Sharma BC, Kumar A. Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial. Hepatol Int 2013;7:248-256. https://doi.org/10.1007/s12072-012-9353-8
- Qi XS, Bao YX, Bai M, Xu WD, Dai JN, Guo XZ. Nonselective beta-blockers in cirrhotic patients with no or small varices: a meta-analysis. World J Gastroenterol 2015;21:3100-3108. https://doi.org/10.3748/wjg.v21.i10.3100
- Bhardwaj A, Kedarisetty CK, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut 2017;66:1838-1843. https://doi.org/10.1136/gutjnl-2016-311735
- Bonilha DQ, Lenz L, Correia LM, et al. Propranolol associated with endoscopic band ligation reduces recurrence of esophageal varices for primary prophylaxis of variceal bleeding: a randomized-controlled trial. Eur J Gastroenterol Hepatol 2015;27:84-90. https://doi.org/10.1097/MEG.0000000000000227
- Tandon P, Abraldes JG, Keough A, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol 2015;13:1189-1196.e2. https://doi.org/10.1016/j.cgh.2014.11.019
- Azoulay D, Castaing D, Majno P, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol 2001;35:590-597. https://doi.org/10.1016/S0168-8278(01)00185-4
- Puente A, Hernandez-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int 2014;34:823-833. https://doi.org/10.1111/liv.12452
- Park SW, Seo YS, Lee HA, et al. Changes in cardiac varices and their clinical significance after eradication of esophageal varices by band ligation. Can J Gastroenterol Hepatol 2016;2016:2198163.
- Mishra SR, Sharma BC, Kumar A, Sarin SK. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol 2011;54:1161-1167. https://doi.org/10.1016/j.jhep.2010.09.031
- Gwon DI, Kim YH, Ko GY, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: a prospective multicenter study. J Vasc Interv Radiol 2015;26:1589-1595. https://doi.org/10.1016/j.jvir.2015.07.011
- Qiao W, Ren Y, Bai Y, Liu S, Zhang Q, Zhi F. Cyanoacrylate injection versus band ligation in the endoscopic management of acute gastric variceal bleeding: meta-analysis of randomized, controlled studies based on the PRISMA statement. Medicine (Baltimore) 2015;94:e1725. https://doi.org/10.1097/MD.0000000000001725
- Procaccini NJ, Al-Osaimi AM, Northup P, Argo C, Caldwell SH Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center U.S. analysis. Gastrointest Endosc 2009;70:881-887. https://doi.org/10.1016/j.gie.2009.03.1169
- Mishra SR, Chander Sharma B, Kumar A, Sarin SK. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Gut 2010;59:729-735. https://doi.org/10.1136/gut.2009.192039
-
Hung HH, Chang CJ, Hou MC, et al. Efficacy of non-selective
${\beta}$ -blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a randomized controlled trial. J Hepatol 2012;56:1025-1032. https://doi.org/10.1016/j.jhep.2011.12.021 - Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011;33:739-747. https://doi.org/10.1111/j.1365-2036.2011.04590.x
- Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis 2004;19:345-349. https://doi.org/10.1023/B:MEBR.0000043980.74574.eb
- Tapper EB, Jiang ZG, Patwardhan VR. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc 2015;90:646-658. https://doi.org/10.1016/j.mayocp.2015.03.003
- Kimer N, Krag A, Moller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123-132. https://doi.org/10.1111/apt.12803
- Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013;108:1458-1463. https://doi.org/10.1038/ajg.2013.219
- Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046. https://doi.org/10.1136/bmj.38048.506134.EE
- Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-1081. https://doi.org/10.1056/NEJMoa0907893
- Garrido M, Turco M, Formentin C, et al. An educational tool for the prophylaxis of hepatic encephalopathy. BMJ Open Gastroenterol 2017;4:e000161. https://doi.org/10.1136/bmjgast-2017-000161
- European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol 2019;70:172-193. https://doi.org/10.1016/j.jhep.2018.06.024
- Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011;106:1646-1653. https://doi.org/10.1038/ajg.2011.157
- Jeong JY, Jun DW, Bai D, et al. Validation of a paper and pencil test battery for the diagnosis of minimal hepatic encephalopathy in Korea. J Korean Med Sci 2017;32:1484-1490. https://doi.org/10.3346/jkms.2017.32.9.1484
- Yoon EL, Jun DW, Jeong JY, et al. Validation of the Korean Stroop test in diagnosis of minimal hepatic encephalopathy. Sci Rep 2019;9:8027. https://doi.org/10.1038/s41598-019-44503-w
- Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011;23:1250-1257. https://doi.org/10.1097/MEG.0b013e32834d1938
- Sidhu SS, Goyal O, Parker RA, Kishore H, Sood A. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int 2016;36:378-385. https://doi.org/10.1111/liv.12921